• Hector R Perez, Michele Buonora, Chinazo O Cunningham, Moonseong Heo, and Joanna L Starrels.
• Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. heperez@montefiore.org.
• J Gen Intern Med. 2020 Jan 1; 35 (1): 36-42.

BackgroundOpioid tapering is increasingly utilized by providers to decrease risks of chronic opioid therapy, but it is unknown whether tapering is associated with termination of care.ObjectiveTo determine whether patients taking chronic opioid therapy who experienced opioid tapers were at greater risk of subsequently terminating their care compared with those who were continued on their doses.DesignRetrospective cohort study of patients in a large, urban health system between 2008 and 2012 with 2 years of follow-up.ParticipantsAdult patients prescribed a stable baseline dose of chronic opioid therapy of at least 25 morphine milligram equivalents per day during a baseline year.Main MeasuresAn opioid taper during an exposure year, defined as a reduction in the average daily dose of at least 30% from the baseline dose in both of the two 6-month periods in the year following the baseline year. Opioid dose continuation was defined as any increase in dose, no change in dose, or any decrease up to 30% compared with baseline dose in the exposure year. The primary outcome was termination of care, defined as no outpatient encounters in the health system, in the year following the exposure year.Key ResultsOf 1624 patients on chronic opioid therapy, 207 (15.5%) experienced an opioid taper and 78 (4.8%) experienced termination of care. Compared with opioid dose continuation, opioid taper was significantly associated with termination of care (AOR 4.3 [95% CI 2.2-8.5]).ConclusionsOpioid taper is associated with subsequent termination of care. These findings invite caution and demonstrate the need to fully understand the risks and benefits of opioid tapers.

13 keywords...

hide…